Crossmark Global Holdings Inc. acquired a new stake in Avantor, Inc. (NYSE:AVTR – Free Report) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 40,951 shares of the company’s stock, valued at approximately $1,059,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Boston Partners lifted its position in Avantor by 2.2% in the first quarter. Boston Partners now owns 28,561,802 shares of the company’s stock valued at $729,298,000 after purchasing an additional 624,369 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in shares of Avantor by 6.8% during the second quarter. Canada Pension Plan Investment Board now owns 22,927,325 shares of the company’s stock valued at $486,059,000 after buying an additional 1,463,695 shares during the period. 1832 Asset Management L.P. increased its stake in shares of Avantor by 1,634.9% during the second quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company’s stock valued at $180,839,000 after buying an additional 8,038,451 shares during the period. Bessemer Group Inc. increased its stake in shares of Avantor by 4.4% during the first quarter. Bessemer Group Inc. now owns 7,099,848 shares of the company’s stock valued at $181,544,000 after buying an additional 297,534 shares during the period. Finally, Robeco Schweiz AG increased its stake in shares of Avantor by 5.0% during the second quarter. Robeco Schweiz AG now owns 6,006,985 shares of the company’s stock valued at $127,348,000 after buying an additional 287,717 shares during the period. Institutional investors own 95.08% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on AVTR shares. Robert W. Baird reduced their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Morgan Stanley boosted their target price on Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, July 29th. TD Cowen upped their price target on Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Stifel Nicolaus upped their price target on Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Finally, Wells Fargo & Company reduced their price target on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, October 28th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Avantor presently has an average rating of “Moderate Buy” and a consensus target price of $27.57.
Avantor Trading Down 2.0 %
NYSE AVTR opened at $21.15 on Friday. Avantor, Inc. has a 12 month low of $18.87 and a 12 month high of $28.00. The stock has a market cap of $14.39 billion, a P/E ratio of 46.91, a P/E/G ratio of 2.63 and a beta of 1.35. The stock’s fifty day moving average price is $24.70 and its 200-day moving average price is $24.05. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84.
Insider Activity
In other news, CAO Steven W. Eck sold 3,525 shares of the company’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the transaction, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at $740,372.64. This represents a 10.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.50% of the company’s stock.
About Avantor
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Recommended Stories
- Five stocks we like better than Avantor
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Which Wall Street Analysts are the Most Accurate?
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTR – Free Report).
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.